|
Patent landscape, scope, and claims: |
US Patent 6,784,197: What Is Claimed and Where It Sits in the Landscape
US Patent 6,784,197 is a composition-of-matter and method-use patent built around a broad genus of substituted pyrrolidinyl amides (Formula I) with extensive variability at the “carbonyl substituent” and multiple ring substituents, plus explicit coverage for racemates, enantiomerically enriched forms, and pure enantiomers, and follow-on embodiments that enumerate specific stereodefined compounds.
What is the core claim structure? (Claim 1 genus)
Claim 1 is the anchor. It defines a compound “having the formula I or a pharmaceutically acceptable salt,” with:
- X is either —CA1NR5R6 or —CA1—R8
- A1 and A2 are independently oxygen, sulfur, or —NR9
- R1 is hydrogen, alkyl, aryl, or —CH2—R1a (with R1a among aryl/halogen/hydroxy/amino/nitro/cyano)
- R3 is broadly selected from large lists including halogens, nitro/cyano/azido, carboxy/amido/sulfonic acid/sulfonamide, multiple alkenyl/alkynyl and heteroaryl systems, and acyl/acyloxy/oxyester/oxyamido plus many substituted linking groups
- R3a is similarly broad (H, halogen, alkyl/alkenyl/alkynyl/aryl)
- R5, R6, R9 each independently range over multiple substituents (including H/hydroxy/alkyl/aryl/alkoxy/acyloxy/oxyester/oxyamido/sulfonyloxy/sulfin yloxy/aryloxy/arylalkoxy)
- R8 is hydrogen or a similar substituent set (hydroxy/thiol/halogen/alkyl/aryl/thio-variants)
- Key provisos narrow certain combinations:
- “at least one of R3 and R3a is other than hydrogen”
- if compound is a mixture of all possible isomers and X is —CONR5R6, A2 is oxygen, and R1 is hydrogen then pyrrolidine-ring substitution is other than mono-/di-methyl or mono-ethyl
- if R1 and R3a are both hydrogen, A2 is oxygen, and X is —CONR5R6, then R3 is different from an enumerated exclusion set (e.g., carboxy/ester/amido certain “substituted oxo-pyrrolidine” classes, multiple linking groups, and specific substituted classes including methyl/naphthyl/phenyl optionally substituted by oxy derivatives or para-halogen)
This makes the genus wide while carving out specific “nearby” variants through combination-based exclusions.
Which substitutions are expressly constrained? (Claims 2–20 narrowing + explicit examples)
Claim 2: X subclassing
Claim 2 refines Claim 1 by selecting X from:
- (a) —CONR5R6
- (b)-(e) —CONR5R6 with R5/R6 restrictions (H vs C1-4 alkyl vs phenyl/alkylphenyl; H vs specific methyl/isopropyl/butyl/tert-butyl variants; or both H)
- (f) —CONH2
This creates a more manufacturable target set: the carbonyl-bearing substituent is heavily focused on amide/urea-like amide embodiments.
Claim 3–5: R1 and R3a
- Claim 3 limits R1 to specific sets (H/alkyl/aryl; lower alkyl like methyl/ethyl/propyl; halogen-substituted aryl; and methylene-bridge-connected R1a)
- Claim 4–5 define R3a as H/alkyl/aryl/aralkyl and halogen/alkyl blends, with “same or different” phrasing driving coverage across small and medium substituent families.
Claim 6–7: R3 (large selectable list) and one additional R1 choice
- Claim 6 is a second high-density substitution gate for R3, offering multiple alternatives (a–f), each with different allowed backbone and functional groups, including:
- heteroaryl attachments (thiazolyl, thienyl, pyrrolyl, furyl, pyridyl variants)
- aryl substitutions (halo, alkyl, haloalkyl, alkoxy, amino, nitro, etc.)
- cyano/azido/amido/carboxy/tetrazole
- alkenyl/alkynyl with halogenation and ring substitution options
- Claim 7 narrows again: R1 to smaller alkyl/aryl sets, including “same substituted by at least one halogen atom,” and an explicit “hydrogen or methyl” option.
Claim 8–10: A2 is oxygen and X is CONR5R6 or CO—R8
Claim 8 locks in:
- A2 = oxygen
- X is —CONR5R6 or —CO—R8
- R1 includes limited atoms (H or alkyl/aryl/halogen/hydroxy/amino/nitro/cyano)
- R3 is selected from a longer list but constrained further to H/halogen plus function-group lists
- R3a defaults to hydrogen in the baseline
- R5/R6 are again constrained to oxygen/sulfur-containing substituent sets (hydroxy/alkyl/aryl alkoxy etc.)
Claim 9 narrows R1 and R3 and pins X to —COOH or —CONH2, while Claim 10 specifies a subset where R1 = methyl/ethyl/n-propyl and X = —CONH2.
Claim 11–13: X as CA1NH2 patterns; R3/R3a structure
Claim 11 introduces a different X architecture explicitly:
- X is —CA1NH2, —CA1NHCH3, or —CA1N(CH3)2
- then R1 and R3 are constrained to smaller/selected functional sets
- includes an allowance where R3 is C2R10 with R10 among cycloalkyl/oxy-substituted sulfonyl or sulfinyl/amine/sulfonyl variants and multiple heteroaryl lists
Claim 12 pins R3a = hydrogen and R3 = hydrogen, then constrains the allowed substituents on alkyl and alkenyl/alkynyl replacements.
Claim 13 narrows the alkylene bridge to methylene and restricts R1 to C1-12 alkyl or C1-6 alkyl or ethyl.
Claims 14–17: Racemic/enantiomer inclusion + substitution exclusions
These claims add explicit compliance rules:
- Claim 14: racemic form plus substitution on pyrrolidine ring excluded from mono-/di-methyl or mono-ethyl under certain X/R1 conditions.
- Claim 15: racemic form plus further exclusion sets when R1 is hydrogen or C1-6 alkyl and R3 is alkenyl/alkynyl or cycloalkyl (unsubstituted).
- Claim 16–17: explicitly define X = —CA1NH2, R1 = H, then detailed sets for R3 including azidomethyl, iodomethyl, halogenated C2–6 alkyl, vinyl variants, acetylene variants, aryl/halogen patterns, and R3a as H/halogen. Both claims cover racemates or enantiomerically enriched forms.
Claims 18–20: Specific embodiment + purity requirement
- Claim 18: A2 oxygen; R1 ethyl; X —CONH2; R3 n-propyl or 2,2-difluorovinyl; R3a hydrogen.
- Claim 19: “pure enantiomer” coverage of the Claim 1 compound.
- Claim 20: when the carbon attached to R1 is asymmetric, it is in the “S”-configuration.
Claims 21–25: Fully enumerated stereodefined compounds + pharmaceutical and method coverage
Claim 21 lists many specific (2S)/(2R) stereodefined structures such as:
- (2S)-2-[4-(bromomethyl)-2-oxo-1-pyrrolidinyl]butanamide
- (2S)-2-[(4R)-4-(iodomethyl)-2-oxopyrrolidinyl]butanamide
- (2S)-2-(2-oxo-4-phenyl-1-pyrrolidinyl)butanamide
- (2S)-2-[4-(iodomethyl)-2-oxo-1-pyrrolidinyl]butanamide
- multiple halomethyl, azidomethyl, isothiocyanatomethyl, vinyl, difluorovinyl, substituted phenyl/tolyl/bromophenyl/chlorophenyl variants
- heteroaryl substitutions (thienyl, thiazolyl, furyl, pyridinyl)
- multiple larger side-chain variants (trifluoromethyl phenyl, biphenyl, propyl/allyl/propyl-substituted pyrrolidinyl)
- includes salts (example: “methyl 4-methylbenzenesulfonate”; “methyl nitrate”; multiple hydrochloride salts)
- includes explicit inclusion of “all isomeric forms and mixtures thereof or pharmaceutically acceptable salt.”
Then:
- Claim 22: pharmaceutical composition with a pharmaceutically acceptable diluent/carrier.
- Claim 23: method of treating a long list of CNS, pain, cardiology, pulmonary, and allergic/respiratory disorders in a mammal, using a therapeutic dose of at least one Claim 1 compound.
- Claim 24–25: method claims explicitly requiring administering a dose of the formula I compound with defined provisos about substituent combinations and pyrrolidine substitution exclusions; Claim 25 is tethered to Claim 21 compounds.
Claims 26–27: narrowed indications
- epilepsy, neuropathic pain, bipolar disorder or migraine.
Claims 28–31: further narrowing
- Claim 28: C1-4 alkylene bridge must be methylene.
- Claim 29: R3 is restricted to methyl/ethyl/propyl/isopropyl/butyl/isobutyl.
- Claim 30–31: R3a is fluorine and the compound is the pure enantiomer (with Claims 16–17 parentage respectively).
How wide is the effective claim scope? (Practical “coverage map”)
1) Scaffold breadth
The claims cover:
- a pyrrolidin-2-one (2-oxo-1-pyrrolidinyl) amidic scaffold (as shown by the consistent enumerated examples in Claim 21)
- with variability at a “ring substitution” region via X, A1/A2, R1, R3, R3a, and R5/R6/R8
The claim structure is a classic genus with substitution lists, then multiple “guardrails” (provisos and exclusions) tied to:
- which of R3 and R3a is non-H
- whether A2 is oxygen
- how substitution behaves when the compound is a mixture of isomers and X/R1 are set
- specific exclusions of functional classes for R3 when certain other variables are both hydrogen.
2) Enantiomer and mixture coverage
Coverage explicitly includes:
- racemic forms (Claims 14–15)
- enantiomerically enriched forms (Claims 16–17)
- pure enantiomer (Claim 19)
- stereochemical constraints like S-configuration at a defined asymmetric carbon (Claim 20)
- multiple enumerated (2S) and (2R) compounds (Claim 21)
This blocks many “design-around” strategies that rely purely on stereochemistry selection.
3) Functional group space
Claim 1 plus dependent claims enumerate a large functional set including:
- amide / carboxyl / ester / ether / sulfonamide / sulfonic acid
- cyano / nitro / azido
- thioethers, thiols, sulfinyl/sulfonyloxy
- alkenyl/alkynyl including halogenated variants
- heteroaryl (thiazole/thiazolyl, thienyl, furyl, pyridinyl, pyrrolyl, tetrazolyl)
The scope is therefore not restricted to a single electrophile or single side-chain family.
Claim-by-claim landmark summary
| Claim |
Role in scope |
What it narrows or expands |
| 1 |
Genus anchor |
Broad Formula I with many substituent lists plus combination-based exclusions |
| 2 |
X refinement |
CONR5R6 and CONH2 forms with R5/R6 restrictions |
| 3–5 |
R1 and R3a |
Smaller alkyl/aryl/halogenated aryl and defined bridge logic |
| 6–7 |
R3 refinement |
Multiple R3 alternatives with detailed functional-group allowances |
| 8–10 |
A2 oxygen + X options |
Constrains R3/R3a and pins X to acid/amide in subsets |
| 11–13 |
X “CA1NH2” family + R3 |
Adds alternative X patterns and C2R10 definition logic |
| 14–17 |
Isomer/mix and enantiomer controls |
Excludes certain ring substitutions in racemic embodiments; covers enriched/pure enantiomers |
| 18–20 |
Specific embodiments + purity |
Defines example-specific R1/X/R3 combos; forces “pure enantiomer” and “S-configuration” |
| 21 |
Example lock |
Enumerates many specific stereodefined structures and salts |
| 22–27 |
Composition and use |
Composition claim; broad method-of-treatment list and narrowed subsets |
| 28–31 |
Additional tightening |
Bridge = methylene; R3 limited; R3a = fluorine with pure enantiomer constraints |
Patent landscape: what this patent likely blocks and what it leaves open
A full US landscape requires bibliographic parsing (continuations, related family members, foreign priority, prosecution history, and later patents). The prompt provides only the US 6,784,197 claim text, not:
- the publication date(s), filing date, priority chain, assignee, examiner, continuations, reissues, or cited references
- any status (granted/expired/active), licensing or litigation history
- any related US application numbers or counterpart EP/WO documents
With that limitation, a “true” competitive landscape cannot be constructed without inventing facts.
What can be stated from the claim language alone is how the patent can shape competition:
1) Design-around pressure zones
Claim 1’s provisos and exclusions create several pressure points where competitors must avoid:
- cases where R3 and R3a are both hydrogen (explicitly barred by “at least one other than hydrogen” plus dependent-exclusion logic)
- certain R3 functional classes under the specific “R1 and R3a both hydrogen + A2 oxygen + X = —CONR5R6” condition
- racemic mixtures where substitution patterns on the pyrrolidine ring fall into the excluded methyl/ethyl patterns under the specified X/R1 conditions
2) Stereo and salt strategy risk
Because Claim 21 includes both (2S) and (2R) entries and Claim 19 covers pure enantiomers, and Claim 21 covers salts:
- choosing stereochemistry alone is unlikely to avoid infringement if the compound still fits the Formula I and enumerated substituent classes
- switching to a different pharmaceutically acceptable salt often does not avoid coverage because Claim 1 and Claim 21 both extend to salts.
3) Indication strategy risk
The method claims (23, 24, 25, 26, 27) cover a very broad indication set and include CNS disorders plus pain and respiratory/allergy conditions. If a therapeutic claim is tied to the chemical structures of Claim 1 or the enumerated Claim 21 compounds, indication selection alone does not eliminate the risk in the US.
What is the strongest “infringement anchor” within the claims?
The enumerated Claim 21 list is the most litigation-ready portion because it:
- names specific stereodefined compounds
- includes salts
- explicitly ties multiple substitutions (halomethyl, azidomethyl, vinyl/difluorovinyl, substituted phenyl/heteroaryl) and ring stereochemistry.
A second anchor is Claim 19/20 (pure enantiomer + S-configuration), because it reduces room for competitors to argue “not the same stereoisomer.”
Key Takeaways
- Claim 1 is a broad genus of substituted pyrrolidinyl amide-like compounds with extensive substituent lists and combination-based exclusions tied to R3/R3a hydrogen status and A2 oxygen with X = CONR5R6.
- Claims 14–20 expand coverage across racemic mixtures, enantiomerically enriched forms, and pure enantiomers, and include stereochemical constraints like S-configuration.
- Claim 21 enumerates many specific (2S)/(2R) compounds and salts, making it the most concrete target set.
- Claims 22–27 add composition and method-of-treatment coverage with an unusually wide indication list, plus narrower subsets.
- A reliable competitive landscape requires prosecution and family data not provided here; however, the claim language indicates the patent blocks a wide band of close chemical variants and does not rely only on racemate-level coverage.
FAQs
-
Is the patent limited to a single molecule or a family of compounds?
It covers a Formula I genus in Claim 1, with many dependent narrowing provisions and an expanded list of specific stereodefined compounds in Claim 21.
-
Does the patent cover enantiomers specifically?
Yes. It explicitly covers racemic forms (Claims 14–15), enantiomerically enriched forms (Claims 16–17), and a pure enantiomer (Claim 19), with S-configuration language (Claim 20).
-
Can a competitor avoid risk by changing to a different salt form?
Claim 1 and Claim 21 both include “pharmaceutically acceptable salts,” including named examples, so salt selection alone is not a safe design-around.
-
Are the method claims tied to many indications?
Yes. Claim 23 lists many CNS, pain, pulmonary, and allergic/vasomotor conditions; Claims 26–27 narrow subsets like epilepsy, neuropathic pain, bipolar disorder, and migraine.
-
Which claim section is most enforceable in practice?
Claim 21 because it enumerates specific stereodefined compounds and salts; it is the most directly map-able to candidate structures.
References
[1] US Patent 6,784,197, claim set as provided in the prompt (Claims 1–31).
More… ↓
⤷ Start Trial
|
